Artificial intelligence chatbots—the conversational software behind tools that answer questions and offer guidance in plain language—are increasingly being floated as helpers for people living with long-term conditions like diabetes, heart disease and other chronic illnesses. A new systematic review takes stock of what the research actually shows.
The paper, titled "The Role of Artificial Intelligence Chatbots in Chronic Disease Care: A Systematic Review of Current Evidence and Future Directions," was published in the medical journal Cureus. As its title indicates, the authors set out to gather and assess the existing evidence on how AI chatbots are being used in chronic disease care, and to map where the field may be heading next.
A systematic review is not a single experiment but a structured survey of the published studies on a topic. That approach is useful here because it pulls scattered findings into one place, helping clinicians, patients and policymakers see the overall picture rather than relying on any one promising-but-isolated result.
The focus on chronic disease is significant. These conditions require ongoing, day-to-day management—monitoring symptoms, sticking to medication schedules, and making lifestyle adjustments—often between relatively brief visits with a doctor. Chatbots are being explored as a way to support patients during those gaps, offering reminders, information and round-the-clock interaction at scale.
Because the review also points to "future directions," it signals that the technology is still maturing and that important questions remain about how, when and whether these tools should be deployed in real care settings.
Why it matters: chronic diseases account for a large share of the world's health burden, and any tool that can reliably extend support beyond the clinic could reshape how millions of patients manage their conditions—making a clear-eyed look at the evidence essential before that promise is treated as proven.